Showing results (311-320 of 517) with videos related to

Sort By:
Pageof 52
Circulation|September 1, 1975
The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosisA Kaegi, G F Pineo, A Shimizu, et al.
Neurology|February 5, 1999
Bilateral optic neuropathy with IgGkappa multiple myeloma improved after myeloablative chemotherapyF S Lieberman, J Odel, J Hirsh, et al.
Lancet (London, England)|November 20, 1998
Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on AnticoagulationL Poller, C R Shiach, P K MacCallum, et al.
Pharmacological Reviews|March 1, 1994
Low molecular weight heparin: a critical analysis of clinical trialsD Green, J Hirsh, J Heit, et al.
Thrombosis and Haemostasis|November 24, 1989
The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacementM N Levine, A Planes, J Hirsh, et al.
Thrombosis Research|November 15, 1982
Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasmaF A Ofosu, G Modi, A L Cerskus, et al.
Archives of Internal Medicine|May 7, 1998
The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative GroupJ R Leclerc, M Gent, J Hirsh, et al.
Thrombosis and Haemostasis|April 25, 1989
Risks to the fetus of anticoagulant therapy during pregnancyJ S Ginsberg, J Hirsh, D C Turner, et al.
Thrombosis Research|December 22, 1999
The binding of unfractionated heparin and low molecular weight heparin to thrombin-activated human endothelial cellsE Young, T Venner, J Ribau, et al.
Thrombosis Research|September 15, 1982
Comparison of the in vivo hemorrhagic and antithrombotic effects of a low antithrombin-III affinity heparin fractionP A Ockelford, C J Carter, A Cerskus, et al.
Pageof 52